Before a planned trip to the U.S., Cheng wanted to get vaccinated against COVID-19. To do so, he asked a friend working at a cold-chain logistics company in southeast China to pretend he was employed by the firm, allowing Cheng access to one of the country’s experimental shots.
Cheng, a business owner from Beijing, now plans to fly to Guangdong province and pay as much as $91 to take two doses of what he believes is a vaccine being produced by a unit of Sinopharm, the state-backed Chinese developer at the front of the global COVID-19 vaccine race.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.